Hansoh Pharma ranked No. 19 among the 100 Top Enterprises in Chinese Pharmaceutical Industry for 2016 released recently by CFDA Southern Medicine Economic Research Institute. In recent years, by closely following national medical policies, Hansoh Pharma has promoted transformation and upgrading through innovative development and has steadily improved its comprehensive strength through joint efforts and integration. In the years ahead, with the launch of innovative drugs in succession, the Company will again achieve great strides.

It was reported that the time period for the selection of the 100 Top Enterprises in Chinese Pharmaceutical Industry for 2016 was from January 1 to December 31, 2016, and the statistical indicator was the the pharmaceutical industry sales income of enterprises in the selection year.